A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer

A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer

Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05733013

Contacts

Locations

Layout table for location information

United States, New York

Memorial Sloan Kettering Cancer Center
**RECRUITING NOW**

New York, New York, United States, 10065

Contact: Laura Boucai, PhD    646-608-3906      

Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
Investigators

Layout table for investigator information

Principal Investigator:
Laura Boucai, MD
Memorial Sloan Kettering Cancer Center

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 18, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments